These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
222 related items for PubMed ID: 31594446
41. Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. Si X, Pan R, Ma S, Li L, Liang L, Zhang P, Chu Y, Wang H, Wang M, Zhang X, Zhang L. Thorac Cancer; 2021 Feb; 12(3):357-363. PubMed ID: 33300283 [Abstract] [Full Text] [Related]
45. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. Press RH, Zhang C, Cassidy RJ, Ferris MJ, Zhong J, Steuer CE, Pillai RN, Owonikoko TK, Kahn S, Ramalingam SS, Patel PR, Curran WJ, Shu HG, Sica GL, Higgins KA. Cancer; 2018 Sep 01; 124(17):3586-3595. PubMed ID: 30120912 [Abstract] [Full Text] [Related]
46. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer. Xie F, Zheng X, Mao X, Zhao R, Ye J, Zhang Y, Sun J. Ann Thorac Surg; 2019 Jul 01; 108(1):219-226. PubMed ID: 30885850 [Abstract] [Full Text] [Related]
47. Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma. Chen L, Liu M, Zhang Y, Guo Y, Chen MH, Chen J. Clin Colorectal Cancer; 2021 Jun 01; 20(2):177-185.e13. PubMed ID: 33041225 [Abstract] [Full Text] [Related]
48. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer. Rice SJ, Liu X, Hyland V, Liu Z, Belani CP. Lung Cancer; 2020 Mar 01; 141():97-100. PubMed ID: 31986371 [Abstract] [Full Text] [Related]
49. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, Guo M, Routbort MJ, Zhang J, Skoulidis F, Heymach J, Roarty EB, Tang Z, Medeiros LJ, Patel KP, Luthra R, Roy-Chowdhuri S. BMC Cancer; 2020 Jan 31; 20(1):83. PubMed ID: 32005111 [Abstract] [Full Text] [Related]
50. NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas. Tlemsani C, Pécuchet N, Gruber A, Laurendeau I, Danel C, Riquet M, Le Pimpec-Barthes F, Fabre E, Mansuet-Lupo A, Damotte D, Alifano M, Luscan A, Rousseau B, Vidaud D, Varin J, Parfait B, Bieche I, Leroy K, Laurent-Puig P, Terris B, Blons H, Vidaud M, Pasmant E. Cancer Med; 2019 Aug 31; 8(9):4330-4337. PubMed ID: 31199580 [Abstract] [Full Text] [Related]
51. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics. Salimian KJ, Fazeli R, Zheng G, Ettinger D, Maleki Z. Acta Cytol; 2018 Aug 31; 62(2):79-84. PubMed ID: 29320776 [Abstract] [Full Text] [Related]
52. Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions. Li W, Qiu T, Ling Y, Gao S, Ying J. Mol Oncol; 2018 May 31; 12(5):677-689. PubMed ID: 29518290 [Abstract] [Full Text] [Related]
53. Mutation Profile of Resected EGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing. Zhao ZR, Lin YB, Ng CSH, Zhang R, Wu X, Ou Q, Chen W, Zhou WJ, Lin YB, Su XD, Shao YW, Long H. Oncologist; 2019 Oct 31; 24(10):1368-1374. PubMed ID: 30872465 [Abstract] [Full Text] [Related]
54. Genomic alterations of ground-glass nodular lung adenocarcinoma. Lee H, Joung JG, Shin HT, Kim DH, Kim Y, Kim H, Kwon OJ, Shim YM, Lee HY, Lee KS, Choi YL, Park WY, Hayes DN, Um SW. Sci Rep; 2018 May 16; 8(1):7691. PubMed ID: 29769567 [Abstract] [Full Text] [Related]
55. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC. Smuk G, Pajor G, Szuhai K, Morreau H, Kocsmár I, Kocsmár É, Pajor L, Kajtár B, Sárosi V, Lotz G, Tornóczky T. Lung Cancer; 2020 May 16; 143():80-85. PubMed ID: 32272316 [Abstract] [Full Text] [Related]
56. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay. Hou H, Yang X, Zhang J, Zhang Z, Xu X, Zhang X, Zhang C, Liu D, Yan W, Zhou N, Zhu H, Qian Z, Li Z, Zhang X. Sci Rep; 2017 Nov 06; 7(1):14605. PubMed ID: 29097733 [Abstract] [Full Text] [Related]
57. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, Howarth K, Beeler JF, Paweletz CP, Oxnard GR. Ann Oncol; 2018 Apr 01; 29(4):1049-1055. PubMed ID: 29325035 [Abstract] [Full Text] [Related]
58. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation. Leblond AL, Rechsteiner M, Jones A, Brajkovic S, Dupouy D, Soltermann A. Am J Clin Pathol; 2019 Jun 05; 152(1):59-73. PubMed ID: 31065676 [Abstract] [Full Text] [Related]
59. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. Zhang C, Zhang J, Xu FP, Wang YG, Xie Z, Su J, Dong S, Nie Q, Shao Y, Zhou Q, Yang JJ, Yang XN, Zhang XC, Li Z, Wu YL, Zhong WZ. J Thorac Oncol; 2019 Nov 05; 14(11):1912-1923. PubMed ID: 31446140 [Abstract] [Full Text] [Related]
60. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma. Xu Y, Chang H, Wu L, Zhang X, Zhang L, Zhang J, Li Y, Shen L, Zhu X, Zhou X, Bai Q. Exp Mol Pathol; 2020 Dec 05; 117():104548. PubMed ID: 32979347 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]